Updated:
Avrobio
Avrobio was established in 2015 by a syndicate of life-sciences investors, with Geoff MacKay assuming the CEO role.
Avrobio
Avrobio was established in 2015 by a syndicate of life-sciences investors, with Geoff MacKay assuming the CEO role. The company traces its intellectual origins to advances in ex vivo lentiviral gene therapy, a modality designed to insert functional genes into a patient’s own hematopoietic stem cells and provide durable, single-dose treatment for rare diseases. Avrobio is headquartered in Cambridge, Massachusetts. The company deploys capital toward a clinical pipeline addressing Fabry disease, Gaucher disease, cystinosis, and Hunter syndrome — all inherited lysosomal storage disorders with significant unmet need. Avrobio’s manufacturing process uses a proprietary plato® platform to maintain genetic stability during vector production, a technical moat that addresses a known failure point in lentiviral therapies. Its Fabry program, AVR-RD-01, reported positive Phase 2 data showing sustained above-normal leukocyte alpha-galactosidase A activity out to four years post-treatment. Avrobio has also progressed AVR-RD-04 for cystinosis into the clinic. In 2023, the company discontinued its Gaucher disease Type 1 program after interim Phase 1/2 data, reallocating resources toward its remaining assets. The company operates solely in the United States and conducts clinical trials at academic sites across North America and Australia. Avrobio remains a small, development-focused biotechnology firm with a headcount that has contracted in response to pipeline rationalization. In May 2023, Avrobio announced a corporate restructuring that included a 30% workforce reduction and an enhanced focus on its Fabry and cystinosis programs (per the firm, May 2023). The company also reported the departure of its chief medical officer, Dr. Essa Quinton, in the same period. Avrobio has no disclosed adjacent vehicles or philanthropic foundations. Avrobio’s structural differentiator is its single-modality conviction in ex vivo lentiviral gene therapy, a space where peers like bluebird bio and Orchard Therapeutics have faced commercial headwinds. By targeting rare lysosomal diseases rather than the more crowded hemoglobinopathy field, Avrobio pursues indications with simpler biology and clearer regulatory endpoints — but also smaller patient populations. The company’s Cambridge base places it within the dense life-sciences labor market, but its lean operations after the May 2023 restructuring enforce discipline on spending in a capital-constrained biotech environment.
General information
Firm type
Asset Manager
Year founded
2015
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, MA, United States
Principals
Geoff MacKay
President and CEO
Sector focus
Frequently asked questions
Which diseases does Avrobio target in its active pipeline?
Avrobio’s clinical pipeline currently focuses on Fabry disease and cystinosis. The Fabry disease program, AVR-RD-01, uses ex vivo lentiviral gene therapy to deliver a functional GLA gene into a patient’s hematopoietic stem cells. The cystinosis program, AVR-RD-04, targets the CTNS gene mutation. Avrobio previously included Gaucher disease and Hunter syndrome programs but discontinued the Gaucher Type 1 arm in 2023 after interim clinical data.
How does Avrobio’s plato® platform work?
The plato® platform is Avrobio’s proprietary lentiviral vector manufacturing system designed to maintain transgene stability during large-scale production. Standard lentiviral vectors are prone to genetic rearrangements that can compromise the therapeutic payload, an issue that has affected multiple gene therapy companies. Plato® reduces this instability by optimizing vector design and production, aiming to preserve consistent potency across batches.
What is the current corporate structure and cash position?
Avrobio remains a lean, publicly traded clinical-stage company. The May 2023 restructuring reduced staff by approximately 30% and trimmed operating expenses, extending cash runway to fund the Fabry and cystinosis programs through key data milestones. The company has not disclosed additional financing rounds beyond its public-market access, and no adjacent family office or foundation vehicles are attached to the firm.
Who runs clinical development decisions at Avrobio?
CEO Geoff MacKay has led Avrobio since its founding in 2015 and is the central decision-maker on pipeline prioritization. The departure of Chief Medical Officer Dr. Essa Quinton in 2023 left a gap in the clinical leadership, and the company has since consolidated operational oversight under a smaller executive team.
How does Avrobio compare to peers like bluebird bio or Orchard Therapeutics?
Avrobio competes in the ex vivo lentiviral gene therapy field but targets a distinct disease cluster: lysosomal storage disorders, rather than the hemoglobinopathies and immunodeficiencies that dominate bluebird bio and Orchard Therapeutics' portfolios. This narrower focus avoids direct competition in larger indications but faces the same modality-specific challenges around vector durability and manufacturing complexity.
Has Avrobio ever partnered with a larger pharmaceutical company?
Publicly disclosed records do not indicate a major strategic partnership with a large pharmaceutical company. Avrobio has historically funded its pipeline through public equity markets and internal research, with no announced licensing or co-development deals.
What is Avrobio's posture on clinical trial geographic expansion?
Avrobio has conducted clinical trials across sites in North America and Australia, consistent with the regulatory pathways for rare-disease gene therapies. There is no disclosed plan to expand into European or Asian trial sites independently, and the company's current cash constraints suggest near-term geographic concentration.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: